drugset / Trial / NCT02930044
Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether adult DKA patients who present to the emergency department treated with early subcutaneous long acting insulin versus standard care receive a shorter total duration of intravenous (IV) insulin infusion.
Timeline
- Start
- 2016-10
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin glargine | Protein / enzyme biologic | 0.3 iu/kg | Subcutaneous |
| Background | Insulin | Protein / enzyme biologic | — | Intravenous |